NCT03968276: APPLIAC

Study of the Interest of Patients Undergoing Anti-thrombotic Treatment in a Digital Application of Therapeutic Assistance

Terminated NA Last updated 2 November 2022

What this trial tests

NA trial testing use of digital tablet in Vascular Diseases in 25 participants. Terminated before completion.

Timeline

21 November 2019

Primary endpoint
10 October 2022

10 October 2022

Quick facts

Lead sponsor	Fondation Hôpital Saint-Joseph
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	25
Start date	21 November 2019
Primary completion	10 October 2022
Estimated completion	10 October 2022
Sites	1 location across France

Drugs / interventions tested

• use of digital tablet

Conditions studied

• Vascular Diseases — all drugs for Vascular Diseases →

Sponsor

Fondation Hôpital Saint-Joseph — full company profile →

Who can join

18 and older, any sex, with Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Medical ethics encourages medical personal to actively care for patients, however old they may be, if they have maintained their physical autonomy and mental integrity to travel the path of medical care together. Many of the patients are in this situation today and their age does not seem to be a limiting factor in the care required.

For more than 60 years, antithrombotics have played a major role in the management of thromboembolic and arterioatheromatous diseases. the doctors have therefore seen the advent of low molecular weight heparins, new platelet antiaggregants and then direct oral anticoagulants.

If their contribution is no longer discussed today, it is necessary to take into consideration the risks they cause, particularly in terms of haemorrhage. Indeed, antithrombotics are the leading cause of serious adverse reactions in France with anti-vitamins K (AVK) which are the leading cause of hospitalization for severe iatrogeny in France. This risk is increased by the coexistence of haemorrhagic risk factors: drug interaction, misuse, failure to comply with contraindications and precautions for use, especially as exposure to these drugs increases with age.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Digital therapeutics in the clinic.
   Phan P, Mitragotri S, Zhao Z. · · 2023 · cited 39× · PMID 37476062 · DOI 10.1002/btm2.10536